Journal of Clinical Epidemiology
Volume 49, Issue 2 , Pages 183-192 , February 1996

Locally advanced non-small cell lung cancer: Do we know the questions? A survey of randomized trials from 1966–1993

  • M.D. Brundage

      Affiliations

    • Corresponding Author InformationAll correspondence should be addressed to: Dr. M. D. Brundage, Radiation Oncology Research Unit, Kingston Regional Cancer Clinic, 25 King St. West, Kingston Ontario, Canada K7L 5P9.
    • The Radiation Oncology Research Unit, Ontario Cancer Treatment and Research Foundation, Queen'S University, Kingston, Ontario, Canada
    • The Kingston General Hospital, Kingston, Ontario, Canada
    • ,
  • W.J. Mackillop

      Affiliations

    • The Radiation Oncology Research Unit, Ontario Cancer Treatment and Research Foundation, Queen'S University, Kingston, Ontario, Canada
    • The Kingston General Hospital, Kingston, Ontario, Canada

,Revised 18 April 1995

References 

  1. DeVita VT. Lung Cancer. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Principles and Practice of Oncology. New York: Lippincott; 1990;
  2. Boring CC, Squires TS, Tong MS, Montgomery S. Cancer statistics, 1994. Ca: Cancer J Clin. 1994;44:7–26
  3. Anonymous Canadian Cancer Statistics. In: Toronto: National Cancer Institute of Canada; 1992;p. 18–19
  4. Novotny TE, Shane P, Daynard RA, Connolly GN. Tobacco use as a sociologic carcinogen: the case for a public health approach. Can Preven. 1992;1–15 July
  5. Green MR. Chemotherapy and radiation in the nonoperative management of stage III non-small-cell lung cancer: the right chemothetapy works in the right setting. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Important Advances in Oncology 1993. Philadelphia: J.B. Lippincott; 1993;p. 125–138
  6. Mackillop WJ, O'Sullivan B, Ward OK. Non-small cell lung cancer: how oncologists want to be treated. Int J Rad Oncol Biol Phys. 1987;
  7. Palmer MJ, O'Sullivan B, Steele R, Mackillop WJ. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol. 1990;19:17–28
  8. Mackillop WJ, Ward GK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer. 1986;54:661–667
  9. Murray N. Chemotherapy for non-small cell lung cancer: a futile or fertile field for clinical research?. Can J Clin Oncol. 1993;3:151–160
  10. Hamilton CS, Denham JW, Joseph DJ, et al.  Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian pattern of practice study. Newcastle Mater Misericordiae Hospital. New South Wales, Australia Clin Oncol. 1992;4:141–147
  11. Priestman TJ, Bullimore JA, Godden TP. The Royal College of Radiologists' Fractionation Survey. Clin Oncol. 1989;1:39–46
  12. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol. 1995;13:1904
  13. Pocock SJ. Introduction: the rationale of clinical trials. In:  Pocock SJ editors. Clinical Trials—A Practical Approach. Toronto: Wiley; 1984;p. 1–13
  14. Hubbatd SM. Information systems in oncology. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott; 1993;p. 2581–2588
  15. Mountain CF. A new international staging system for non-small cell lung cancer. Chest. 1986;89:225s–233s
  16. Nagy-Mignotte H, Bolla M, Wuyam B, et al.  Sequential combination of 5-fluorouracil, cis-platinum and irradiation in unresectable non-small cell lung cancer. Radiother Oncol. 1989;15:333–339
  17. Havemann K, Wolf M, Gorg C, Hackenbruch E, Pfab R, Gorg K. Preclinical and clinical experience with cisplatin and carboplatin and simultaneous radiation in non-small cell lung cancer. Ann Oncol. 1992;3(3):33–37
  18. Gomm SA, Thatcher N, Cuthburt A, et al.  High dose combination chemotherapy with ifosfamide, cyclophosphamide orcisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase study. Br J Cancer. 1991;63:293–297
  19. Mackillop WJ, Palmer MJ, O'Sullivan B, Quirt CF. The Expert Surrogate System. In:  Williams CJ editors. Introducing New Treatments for Cancer. Toronto: Wiley and Sons; 1992;p. 459–478
  20. Perez CA, Pajak TF, Rubin P, et al.  Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987;59:1874
  21. Hazuka MB, Turrisi AT. The evolving role of radiation therapy in the treatment of locally advanced lung cancer. In: 3rd Ed. Semin Oncol. 20:1993;p. 173–184
  22. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–145
  23. O'Sullivan B, Mackillop WJ. An approach to the interpretation of the literature of head and neck cancer. Clin Oncol. 1986;5:411–433
  24. O'Sullivan B, Mackillop W, Gilbert R, et al.  Controversies in the management of laryngeal cancer: results of an international survey of patterns of care. Radiother Oncol. 1994;31:23–32
  25. Mike V. Philosophers assess randomized clinical trials: the need for dialogue. Control Clin Trials. 1989;10:244–253
  26. Hellman S, Hellman DS. Of mice but not men: problems of the randomized clinical trial. N Engl J Med. 1991;324:1585–1589
  27. Passamani E. Clinical trials—are they ethical?. N Engl J Med. 1991;324:1589–1591
  28. Eddy DM. In: 3rd Ed. A Manual for Assessing Health Practices and Designing Practice Policies. Philadelphia: American College of Physicians; 1992;p. 5–15
  29. Brundage MD, Davidson JR. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. Clin Invest Med. 1994; Aug (suppl) (Abstract)
  30. Silverman WA. The public character of scientific medicine. Perspect Biol Med. 1993;26:343–353
  31. Mackillop WJ, Dixon P, Zhou Y, et al.  Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol. 1994;32:106–115
  32. Trovo MG, Minatel E, Franchin G, et al.  Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Rad Oncol Biol Phys. 1992;24:11–15
  33. Dillman RO, Seagren SL, Propert KJ, et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–945
  34. Anonymous Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 1991;63:265–270
  35. Anonymous A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1992;65:934–941
  36. Hilden J, Habbema JDF. The marriage of clinical trials and clinical decision science. Stat Med. 1993;
  37. Veatch RM, Moreno JD. Consensus in panels and committees: conceptual and ethical issues. J Med Phil. 1991;16:371–373
  38. Wachter RM. AIDS, activism, and the politics of health. N Engl J Med. 1992;326:128–133
  39. Gibson B. Breast cancer activists call for more research, more compassion. Can Med Assoc J. 1993;148:254–256

☆ This work supported in part from the National Cancer Institute of Canada.

PII: 0895-4356(95)00518-8

Journal of Clinical Epidemiology
Volume 49, Issue 2 , Pages 183-192 , February 1996

Article Tools